Invesaro

Stocks Health care LIPO

Health care

Lipella Pharmaceuticals Inc. (LIPO)

It posted a net loss of $5.3M. At September 30, 2025 it held $1.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 14, 2025.

Free, no password. An email when LIPO files with the SEC.

Price
$0.00
0.00% on the day · November 9, 2026
52-week range $0.00 to $0.55
Market cap
$2.3K

Key facts about Lipella Pharmaceuticals Inc.

Net worth
Lipella Pharmaceuticals Inc. has a market value (market cap) of $2.3K at the latest share price, and shareholders' equity of $1.5M on its balance sheet at September 30, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit
In fiscal 2024 revenue was $536.4K (+19.3% year on year), with a net loss of $5M.
Cash flow
In fiscal 2024 operations used $4M of cash.
Latest report
The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 14, 2025 and covers the period to September 30, 2025. Open on SEC EDGAR

What Lipella Pharmaceuticals Inc. does

Lipella Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations).

Revenue and profit by year

Revenue
FY22: $259.3K $259.3K FY22FY22: $184.2K $184.2K FY22FY23: $449.6K $449.6K FY23FY24: $536.4K $536.4K FY24
Net income
FY22: -$1.9M -$1.9M FY22FY22: -$2.6M -$2.6M FY22FY23: -$4.6M -$4.6M FY23FY24: -$5M -$5M FY24

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2024$536.4K-$5.1M-$5M-$4.79n/a
2023$449.6K-$4.7M-$4.6M-$6.16-$3.2M
2022$184.2K-$2.6M-$2.6M-$5.12n/a
2022$259.3K-$1.9M-$1.9M-$4.40n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where LIPO ranks in Health care

Revenue$536.4K
#680 of 751 in Health care · Bottom 9%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Lipella Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. July 15, 2026
  2. March 31, 2026
  3. February 4, 2026
  4. November 14, 2025
    Quarterly report 10-Q · period to September 30, 2025Diluted EPS -$0.28 versus -$1.29.
  5. October 21, 2025
  6. October 9, 2025
  7. October 6, 2025
  8. September 18, 2025
  9. August 14, 2025
    Quarterly report 10-Q · period to June 30, 2025Revenue fell 36% to $86.7K versus the same quarter last year; diluted EPS -$0.31 versus -$0.99.
  10. June 25, 2025

Recent insider filings (Forms 3, 4 and 144): 6, the latest on April 7, 2025. Insider transactions on SEC

Insider trades

What the people running Lipella Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about LIPO

What does Lipella Pharmaceuticals Inc. do?

Lipella Pharmaceuticals Inc. is a company in the Health care sector.

What is Lipella Pharmaceuticals Inc.'s net worth?

Lipella Pharmaceuticals Inc. has a market value (market cap) of $2.3K at the latest share price, and shareholders' equity of $1.5M on its balance sheet at September 30, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Lipella Pharmaceuticals Inc. profitable?

No. Over the twelve months to September 30, 2025 it reported a net loss of $5.3M.

When did Lipella Pharmaceuticals Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 14, 2025. It covers the period to September 30, 2025. Its newest filing of any kind is the bankruptcy or receivership from July 15, 2026.

Similar companies

Compare LIPO with

Compare LIPO with any company

Follow LIPO

Get an email when Lipella Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Free, no password. An email when LIPO files with the SEC.

Where the numbers come from

Financial figures are the values Lipella Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.